Genetically engineered primary oligodendrocytes for transplantation-mediated gene delivery in the central nervous system
CA 2247912 A1 · Owner: Mckinnon, Randall D. · Inventors: Mckinnon, Randall D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention pertains to a method for transplanting genetically engineered primary cells into the central nervous system of a patient. The method comprises the steps of (a) isolating primary oligodendrocyte progenitor cells from the brain of a patient; (b) expanding the cells in vitro with mitogens; (c) genetically engineering the cells by introducing transgenes through an eukaryotic expression vector for DNA-mediated gene transfer into the cells; and (d) transplanting the genetically engineered primary cells into the brain of the patient.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 28, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 28, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 28, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.